Oesophageal cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up

J 2016

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

LORDICK, F.; C. MARIETTE; K. HAUSTERMANS; Radka OBERMANNOVÁ; D. ARNOLD et al.

Základní údaje

Originální název

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Autoři

LORDICK, F.; C. MARIETTE; K. HAUSTERMANS; Radka OBERMANNOVÁ a D. ARNOLD

Vydání

Annals of Oncology, Oxford, Oxford University Press, 2016, 0923-7534

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 11.855

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00094110

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; BARRETTS-ESOPHAGUS; JUNCTIONAL CANCER; ESPEN GUIDELINES; OPEN-LABEL; SURGERY; METAANALYSIS; MULTICENTER

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 4. 2017 15:05, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Oesophageal cancer is the 19th most common cancer in the European Union (EU), with cca 45 900 new cases diagnosed in 2012 (1% of the total). In the EU, the highest age-standardised incidence rates for oesophageal cancer are in the Netherlands for men and the UK for women [1]. Variation between countries is high and may reflect different prevalence of risk factors, use of screening and diagnostic methods.

Citovat

LORDICK, F.; C. MARIETTE; K. HAUSTERMANS; Radka OBERMANNOVÁ a D. ARNOLD. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. Oxford: Oxford University Press, 2016, roč. 27, Supplement 5, s. "v50"-"v57", 8 s. ISSN 0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdw329.

@article{1378076,
   author = {Lordick, F. and Mariette, C. and Haustermans, K. and Obermannová, Radka and Arnold, D.},
   article_location = {Oxford},
   article_number = {Supplement 5},
   doi = {https://doi.org/10.1093/annonc/mdw329},
   keywords = {RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; BARRETTS-ESOPHAGUS; JUNCTIONAL CANCER; ESPEN GUIDELINES; OPEN-LABEL; SURGERY; METAANALYSIS; MULTICENTER},
   language = {eng},
   issn = {0923-7534},
   journal = {Annals of Oncology},
   title = {Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up},
   volume = {27},
   year = {2016}
}

TY  - JOUR
ID  - 1378076
AU  - Lordick, F. - Mariette, C. - Haustermans, K. - Obermannová, Radka - Arnold, D.
PY  - 2016
TI  - Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
JF  - Annals of Oncology
VL  - 27
IS  - Supplement 5
SP  - "v50"-"v57"
EP  - "v50"-"v57"
PB  - Oxford University Press
SN  - 09237534
KW  - RANDOMIZED CONTROLLED-TRIAL
KW  - PHASE-III TRIAL
KW  - NEOADJUVANT CHEMORADIOTHERAPY
KW  - BARRETTS-ESOPHAGUS
KW  - JUNCTIONAL CANCER
KW  - ESPEN GUIDELINES
KW  - OPEN-LABEL
KW  - SURGERY
KW  - METAANALYSIS
KW  - MULTICENTER
N2  - Oesophageal cancer is the 19th most common cancer in the European Union (EU), with cca 45 900 new cases diagnosed in 2012 (1% of the total). In the EU, the highest age-standardised incidence rates for oesophageal cancer are in the Netherlands for men and the UK for women [1]. Variation between countries is high and may reflect different prevalence of risk factors, use of screening and diagnostic methods.
ER  -

LORDICK, F.; C. MARIETTE; K. HAUSTERMANS; Radka OBERMANNOVÁ a D. ARNOLD. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. \textit{Annals of Oncology}. Oxford: Oxford University Press, 2016, roč.~27, Supplement 5, s.~''v50''-''v57'', 8 s. ISSN~0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdw329.

Přehled o publikaci